Unknown

Dataset Information

0

Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in kidneys via proliferation-related signalling pathways.


ABSTRACT: BACKGROUND AND PURPOSE:Renal fibrosis acts as the common pathway leading to the development of end-stage renal disease. Previous studies have shown that resveratrol has anti-fibrotic activity, but its potential molecular mechanisms of action are not well understood. EXPERIMENTAL APPROACH:The anti-fibrotic effects of resveratrol were assayed in a rat model of unilateral ureteral obstruction (UUO) in vivo and in fibroblasts and tubular epithelial cells (TECs) stimulated by TGF-?1 in vitro. Gene and protein expression levels were analysed by PCR, Western blotting, and immunohistochemical staining. KEY RESULTS:Resveratrol inhibits the myofibroblastic phenotype and fibrosis formation in UUO kidneys by targeting fibroblast-myofibroblast differentiation (FMD) and epithelial-mesenchymal transition (EMT). The anti-fibrotic effects of resveratrol correlated with decreased proliferation of TECs in the interstitium and tubules, resulting in suppressed activity of the proliferation-related signalling pathways, including that of the MAPK, PI3K/Akt, Wnt/?-catenin, and JAK2/STAT3 pathways. Resveratrol treatment suppressed TGF-?1-induced FMD and the expression of the myofibroblastic phenotype in fibroblasts in vitro by antagonizing the activation of proliferation-related signalling. Similarly, TGF-?1-mediated overactivation of the proliferation-related signalling in TECs induced EMT, and the myofibroblastic phenotype was suppressed by resveratrol. The anti-fibrotic and anti-proliferative effects of resveratrol were associated with the inactivation of Smad2/3 signalling and resulted in a partial reversal of FMD and EMT and the inhibition of the myofibroblastic phenotype. CONCLUSIONS AND IMPLICATIONS:Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in vivo and in vitro via proliferation-related pathways, making it a potential therapeutic agent for preventing renal fibrosis.

SUBMITTER: Zhang X 

PROVIDER: S-EPMC6965682 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in kidneys via proliferation-related signalling pathways.

Zhang Xing X   Lu Hong H   Xie Shuangshuang S   Wu Cunzao C   Guo Yangyang Y   Xiao Yanyi Y   Zheng Shizhang S   Zhu Hengyue H   Zhang Yan Y   Bai Yongheng Y  

British journal of pharmacology 20191128 24


<h4>Background and purpose</h4>Renal fibrosis acts as the common pathway leading to the development of end-stage renal disease. Previous studies have shown that resveratrol has anti-fibrotic activity, but its potential molecular mechanisms of action are not well understood.<h4>Experimental approach</h4>The anti-fibrotic effects of resveratrol were assayed in a rat model of unilateral ureteral obstruction (UUO) in vivo and in fibroblasts and tubular epithelial cells (TECs) stimulated by TGF-β1 in  ...[more]

Similar Datasets

| S-EPMC6849313 | biostudies-literature
| S-EPMC9151716 | biostudies-literature
| S-EPMC5686208 | biostudies-literature
| S-EPMC7404302 | biostudies-literature
| S-EPMC3652183 | biostudies-literature
| S-EPMC3175442 | biostudies-literature
| S-EPMC8241719 | biostudies-literature
| S-EPMC1171183 | biostudies-other
| S-EPMC8178255 | biostudies-literature
| S-EPMC2845279 | biostudies-literature